Onconova Therapeutics Inc., of Princeton, N.J., appointed Jerome Groopman chairman of its clinical advisory board, which will include James Holland, Ross Donehower, Stephen Nimer and William Hait.

Organon Pharmaceuticals USA Inc., of Roseland, N.J., appointed James Harmon vice president, managed markets.

Rho Capital Partners, of New York, appointed Martin Vogelbaum partner.

Sirna Therapeutics Inc., of Boulder, Colo., appointed Keith Yamamoto to its scientific advisory board as chairman, and promoted Barry Polisky to chief scientific officer and senior vice president of research.

Sosei Co. Ltd., of Tokyo, appointed David Chiswell nonexecutive chairman.

The biolitec Group, of Jena, Germany, appointed Carl Siekmann vice president, corporate development.

Theratechnologies Inc., of Montreal, appointed Chantal Desrochers vice president, business development and commercialization.

Topigen Pharmaceuticals Inc., of Montreal, appointed Gary Lessing and Michael Atkin to its board.

Transport Pharmaceuticals Inc., of Framingham, Mass., appointed Tom Amick to its board.

Trubion Pharmaceuticals Inc., of Seattle, added Leander Lauffer as senior vice president of business development and corporate strategy.

V.I. Technologies Inc., of Watertown, Mass., appointed Herb Hooper, Eric Linsley and John Fletcher to its board.

Viropro Pharma, of Montreal, appointed Jean-Marie Dupuy to its scientific advisory committee.

Visient Therapeutics, of Seattle, appointed David Saperstein to its scientific advisory board.